Department of Pathology, Medical University of Graz, Graz, AustriaPulmonary and mediastinal pathology
Retired Professor of the Medical University of Graz
The former director of the Pathology Institute of the Medical University of Graz
The founding chairperson of the Pulmonary Pathology Working Group of the European Society of Pathology (ESP)
Core members of the Interstitial Lung Disease Classification Committee of the American Thoracic Society (ATS) / European Respiratory Society (ERS)
1. Clinical Research Center (CRC), Medical Pathology Center (MPC), Cancer Early Detection and Treatment Center (CEDTC) and Translational Medicine Research Center (TMRC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China
2. Chongqing Technical Innovation Center for Quality Evaluation and Identification of Authentic Medicinal Herbs, Chongqing, China
3. School of Medicine, Chongqing University, Chongqing, China
4. Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, ChinaTumor immune regulation mechanism; Synergistic mechanism of tumor epigenetics and immunity
Chief Physician, Professor and Doctoral Supervisor of Three Gorges Hospital, Chongqing University
Director of the Medical Pathology Center, Clinical Research Center, Early Diagnosis and Treatment Center for Tumors and Translational Medicine Research Center
Director of the Middle Line (NUT) Cancer Specialty
Clinical Focus: Early diagnosis and standardized treatment of tumors, including the establishment of the first national NUT midline carcinoma specialty and the creation of an integrated diagnosis and treatment platform for this disease. Research Focus: Anti-tumor clinical drug development and translational research; research on tumor immune regulation mechanisms; research on the synergistic mechanism of tumor epigenetics and immunity. Currently Responsible Projects: Obtained 5 clinical approval documents for national 1.1 class new drugs; led the formulation of 1 national expert consensus and participated in the formulation of 1 consensus; won the first prize of the China Industry-University-Research Cooperation Innovation Award (individual), the first prize of the China Invention Association's Entrepreneurship and Innovation Award (1/6), the first prize of the Ministry of Education's Scientific and Technological Progress Award (6/16), and the second prize of the provincial and ministerial scientific and technological progress award (6/8); applied for over 20 national invention patents and software copyrights, with 5 authorized; published over 110 SCI papers, including over 50 as first or corresponding author; research results published in Nature, Advanced Science, Science Translational Medicine, JCI, J Hepatol, Circulation Research, Nature Communication, etc.; led 1 sub-project of the National Key Research and Development Program and 2 National Natural Science Foundation of China general projects. Main Academic Appointments: President of the Digital Healthcare Committee of the China Food and Drug Safety Enterprise Quality Promotion Association (FDSA), Vice Chairman of the Integrated Lung Cancer Prevention and Screening Committee of the China Anti-Cancer Association, Chairman of the NUT Midline Carcinoma Gene Diagnosis Working Group of the Gene Diagnosis Committee of the China Anti-Cancer Association, Vice President of the Overseas Chinese Association of Science and Technology and the Liaison Officer of Chongqing.
Department of Medical Oncology, Antwerp University Hospital, Edegem, BelgiumGynecologic oncology; Head and neck oncology
Emeritus Professor of Oncology, Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
His main fields of interest are gynecologic oncology, and head and neck oncology. In addition, he co-ordinated large trials in breast and colon cancer. His main research areas concern early clinical and pharmacological studies with new drugs, studies on the interaction of chemotherapy and radiation therapy and HPV in various malignancies. He devotes a significant amount of time to teaching, professional training, and continuing medical education.
Professor Vermorken serves on the editorial board of six international journals, reviewer of 13 cancer journals and author or co-author of more than 500 publications. He is Editor-in-Chief of ONCO since 2007. As of January 1, 2009 he is Editor-in-Chief of Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology.
National Cancer Center, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, ChinaPalliative therapy; Cancer supportive therapy
Associate Chief Physician of the Comprehensive Department of the Cancer Hospital of the Chinese Academy of Medical Sciences
Doctor of Oncological Surgery from Peking Union Medical College
Dr. Bian has been engaged in the clinical work of comprehensive treatment, palliative treatment and emergency treatment of abdominal tumors for a long time. In 2014, he was the first to carry out the implantation surgery of infusion port via the internal jugular vein in the hospital. Has published over 10 first-author papers, participated in the compilation of 3 books, participated in the translation of 1 book, and has undertaken several clinical research projects.
Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, ItalyMultifunctional polymeric bioconjugates; Tumor; Polymeric micelles; Supramolecular systems; Physical and chemical polymer bioconjugtion
Paolo Caliceti is a member of Editorial Boards of multiple pharmaceutical journals and, since 2018, he is serving as Associate Editor of the Journal of Controlled Release. He has been a member of national and international review panels for research projects, including the European Research Council and the Innovative Medicine Initiative, and as consultant with Italian and International pharmaceutical companies.
His research activity is related to the synthesis, characterization and preclinical validation of targeted drug delivery systems to improve drug bioavailability, stability, local delivery, active and passive targeting, and controlled delivery. The activities of the Caliceti ‘s research groups are mostly centered around protein PEGylation; nano- and micro-particle development by supercritical techniques; stimuli sensitive and targeted polymer bioconjugates, gold nanoparticles, micelles, liposomes and polymersomes, supramolecular assemblies for protein and oligonucleotide delivery.
Paolo Caliceti has co-authored over 180 papers and is the co-inventor of 17 patents.
Instituto de Biomedicina de Sevilla, Consejo Superior de Investigaciones Científicas, Avda. Manuel Siurot s/n, Seville, SpainIdentification of new genes involved in cancer; Its characterization and translation to clinic; Identification and validation of new targets for anticancer drug discovery
Head of the Assay Development Group at the Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid
Leader of the Molecular Biology of Cancer Lab in Biomedical Institute of Seville (IBiS/CSIC)
University of Turin, Turin, ItalySignal transduction; PI3K; Cancer; Heart failure; Inflammation
Emilio Hirsch is Professor of Experimental Biology in the Medical School, University of Torino since 2005. He has authored more than 200 scientific publications that received more than 18000 citations. He is an internationally recognized scientist, elected member of the European Molecular Biology Organization (EMBO), Fellow of the International Society of Heart Research (ISHR) and receiver of the American Association for Cancer Research (AACR) innovator prize. He contributed seminal work in the
characterization of key signal transduction enzymes named PI3Ks with publications in Science, Nature and Cell. He was involved in the identification of the first PI3K inhibitors for the treatment of cancer and
inflammation. His experience in drug discovery was seminal to the design of Kither’s KITCL27. He discovered the scaffolding function of PI3Kgamma that led to the design of Kither’s KIT2014.
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, ItalyIdentification and characterization of gene and transcriptional signaling alterations involved in tumor development and progression, as well as on the validation of their diagnostic, prognostic and predictive significance
The Hormel Institute, University of Minnesota, Austin, TX, USAHepatocellular carcinoma (HCC); Cholangiocarcinoma (CCA); Polycystic liver diseases (PLD); Primary cilia mediated regulation of the cell growth and cellular metabolism; Ciliotherapy and drug development that induce the inhibition of HDACs proteins, especially proteins that inhibit cilia formation in cancer and cystic liver cells
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, GreeceSignal transduction in solid tumors; Transcription factors; Cancer mechanobiology
Athanasios G. Papavassiliou is a Professor of Biochemistry and is Head of the Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Greece. He obtained his MD from the School of Medicine of the Aristotle University of Thessaloniki, Greece (1984) and his PhD from Columbia University, New York, USA (1989). He pursued postdoctoral training at the Department of Microbiology, College of Physicians & Surgeons of Columbia University and at the EMBL, Heidelberg, Germany (1989-1991), where he then served as Staff Scientist (faculty position; 1991-1996). He has published 549 original research and review articles in international peer-reviewed journals [2021 JCR® CIF: 5000 MIF: 9.277; h-index: 92; i10-index: 392; total citations: >28651]. He has been the recipient of numerous national and international research awards, among them the prestigious “ICAAC Young Investigator Award” for excellence in research in the broad areas of microbiology and infectious diseases (1990, American Society for Microbiology). He has also been awarded the degree of ‘Doctor Honoris Causa’ from the Faculty of Health Sciences-School of Medicine, University of Patras, Greece (2013). He is an Honorary Member from Abroad of the Romanian Academy of Medical Sciences (elected in 2022). His research interests focus on the study of signal transduction to transcription factors in cell differentiation, tumorigenesis (cancer mechanomedicine), and certain disease pathobiologies.
Department of Pharmacology, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN, USAMolecular & systems pharmacology; Cancer/molecular biology; Diagnostics; Therapeutics; Systematic review and meta-analysis of RCTs in areas of general internal medicine, nutrition, pharmacology, therapeutics, and obstetrics and gynecology
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USACancer biology; Genetics; Genomics; Cancer cell lines; Cancer biomarkers; Tumor models; Animal models; Patient-derived xenograft models; Vaccines; Breast cancer; Inflammatory breast cancer; Canine mammary tumors; Canine tumors
Division of Digestive Surgery, European Institute of Oncology IRCCS, Milan, ItalyOncology; Surgery; Laparoscopic surgery; Colorectal surgery; Cancer surgery
He has conducted research that has resulted in publications in international journals in the field of minimally invasive laparoscopic and robotic surgery for colorectal cancer. He has also published research on the role of surgery in the multimodal treatment of gastroenteropancreatic neuroendocrine tumors. He is actively involved in national and international educational meetings as a lecturer, particularly due to his experience in the field of neuroendocrine tumors.
Memorial Sloan-Kettering Cancer Center, New York, NY, USACancer biomarkers and therapeutics; Cancer immunology; Molecular bioimaging; Nanomedicine; Drugs screening for anti-cancer activity; Chemoresistance; Antibody development; Medical radiation countermeasures
1. The Lefcourt Family Cancer Treatment and Wellness Center, Englewood Health, Englewood, NJ, USA
2. Icahn School of Medicine at Mount Sinai, New York, NY, USA
3. Hackensack Meridian School of Medicine, Nutley, NJ, USAPancreatic cancer; Gastric cancer; GI neuroendocrine cancer; Minimally invasive surgical approaches for cancer; Molecular genetics of GI malignancies; Surgical treatment of colorectal liver metastases; Quality issues in surgical oncology
Dr. Steven Brower is a faculty member at Hackensack Meridian School of Medicine, Nutley, New Jersey, USA. He is a surgical oncologist with extensive clinical and research experience in gastrointestinal and hepatobiliary cancers. Dr. Brower has contributed to numerous academic publications and is actively involved in cancer education, clinical trials, and multidisciplinary care initiatives.
Department of Medicine, Center for Translational Medicine, Thomas Jefferson University. Philadelphia, PA, USATumor immunology; Cell cycle; Retinoblastoma protein and cancer; Prostate cancer; Breast cancer; Lung cancer
A translational cancer biologist with more than 40 publications in high-tier journals. The work mainly focuses on mitigating prostate, breast and lung cancers by rewiring the tumor suppressor RB via small molecular inhibitors and ionizing radiation.
1. Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
2. Professor Emeritus, School of Human Sciences, The University of Western Australia, Perth, Australia
3. Adjunct Professor, Curtin Medical School, Curtin University, Perth, AustraliaCancer; Wnt signalling; Secreted frizzled related protein-4; Cancer stem cells; Angiogenesis; ROS signalling
Professor, Department of Biomedical Sciences, Arthur A Dugoni School of Dentistry, University of the Pacific, San Francisco, CA, USAPhage therapy of mycobacterial infections; Photodynamic therapy and gene therapy of oral cancer; Eradication of HIV-infected cells by suicide gene therapy
Department of Experimental Research (Cancer Institute), Cancer Center, Sun Yat-sen University, Guangzhou, ChinaMultidrug resistance; Tyrosine kinase inhibitor; ABC transporters; Exosomes; Cancer; Cancer stem cells
Li-wu Fu, Ph.D., Professor, Doctoral Supervisor. Prof. Fu obtained his PhD in the field of Cancer Pharmacology from the Sun Yat-sen University and carried out his doctoral research in South Carolina Medical University from 1999 to 2001.
Prof. Fu’s field of expertise includes anticancer drug pharmacology, molecular mechanism of anticancer drugs and individual cancer chemotherapy. In recent years, he mainly focused on the study of molecular mechanism of anti-cancer drugs, drug resistance of cancer cells (especially multidrug resistance), the innate resistance of cancer stem cells and the individual cancer chemotherapy. For the excellent work in the research of “Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells”, Prof. Fu’s team gained the first prize of “Chinese Anti-Cancer Association (CACA) Science and Technology Award” (Ranked first) and the second prize of “Institute of Higher Education Outstanding Scientific Research Achievements Award” (Natural Science Award) in 2011.
As the leader of the research group, he has won the provincial and ministerial level scientific and technological awards for several times, including the “Outstanding young scientific and technological talents award from Ministry of Health”, the “Servier outstanding young workers Pharmacology Award” and the “Ding Ying Science Award” in 2011.
Prof. Fu has presided over and successfully completed more than 40 key research projects on national, provincial and ministerial scale and horizontal fund projects.
More than 200 research papers have been published and up to 100 papers have been published in high-quality SCI journals, including Cancer Res (6 articles), Oncotarget, Mol Med, Cell Cycle, Eur J Cancer, Mol Cancer Ther, Birth J Parmacol, Biochem Pharmacol , Mol Pharmacol etc. and 10 invention patents have been attained.
División de Genética, Centro de Investigación Biomédica de Occidente (CIBO), Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, MexicoCancer research; Gene; Genetics; in silico; Machine learning; Molecular biology
Amsterdam UMC - University of Amsterdam, Amsterdam, NetherlandsOncology; Gene therapy; Cell therapy; Cancer research; Genomics; Transcriptomics
Team Leader Cell Therapy at the Amsterdam UMC.
Dr. Geerts currently works as Team Leader Cell Therapy at the AmsterdamUMC. He is in charge of the CAR-T programs for treating cancer patients with immune cell therapy. Dirk did academic research in Gene and Cell Therapy in Cancer and Cardiovascular Disease. He is further actively involved in Cell Biology and Genetics with many different groups worldwide.
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata, ItalyNatural product; Cancer; Oxidative stress biomarkers; Modulatory action of nuclear receptors; Adipokines in the development and progression of breast cancer
Associate Professor at the Department of Pharmacy, Health and Nutritional Sciences, University of Calabria.
1. Department of Pathology, Duke University School of Medicine, Durham, NC, USA
2. Duke Cancer Institute, Durham, NC, USALymphoma; Biomarker; Molecular and genetic profiling
Stempel College of Public Health, Florida International University, Miami, FL 33199, USAPediatric cancers; COVID-19; Cardiovascular disease, Kidney disease, Neurological disorders, Radiology
Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University, Lanzhou, ChinaTranslational neuroscience; Neurodevelopment; Axon regeneration; Gliomagenesis; Epigenetics
Executive Director of the Center for Frontier Innovation in Medicine, academic doctoral supervisor, and academic master's supervisor. Member of the Standing Committee of the Translational Medicine Committee of the Chinese Microcirculation Association; member of the Integrative Oncology Committee and young member of the Nano-Oncology Committee of the Chinese Anti-Cancer Association; member of the Chinese Society of Neuroscience; correspondence reviewer of the National Natural Science Foundation of China; member of the International Cancer Epigenetics Society; international reviewer of The Brain Tumour Charity Foundation in the UK; international reviewer of post-doc fellowship applications in France.
USC Michelson Center Convergent Science Institute in Cancer, Los Angeles, CA, USACancer; Metastasis; Cancer stem cells; Circulating tumor cells; Liquid biopsy; Biomarker; Prognosis
1. Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
2. Department of Pharmacy, Faculty of Health and Life Sciences, Daffodil International University, Birulia, Savar, Dhaka, Bangladesh
3. Centre for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, India
4. Novel Global Community Educational Foundation, Hebersham, AustraliaEnzymoics; Neurobiology; Nanotechnology
Department of Pharmacology & Immune Network Pioneer Research Center, Ajou University School of Medicine, Suwon, South KoreaBioprinting; Application of 3D hybrid NFS-based immune-network chip to several disease models; Lymphoma; Melanoma; Colon cancer; Inflammatory diseases
Department of Biopharmaceutical Chemistry, School of Applied Chemistry, Kookmin University, Seoul, South KoreaNanobody; Antibody discovery and development; Bispecific antibody; Antibody drug conjugate; Neutralizing antibody; Bifunctional antibody repeats for potent and broad neutralization of SARS-CoV-2 variants
Department of Neurological Surgery, Rush University Medical Center, Chicago, USAAlzheimer's disease; Brain tumors; Imaging; Immunotherapy; Medical neurosciences; Neurobiology; Spine surgery; Thyroid
Associate Professor in Department of Neurological Surgery at Rush University, Chicago, USA. He has a number of research interests, and his brain tumor work is largely focused on the development of a DNA vaccine for treatment of primary and metastatic intracerebral tumors. In particular Dr. Lichtor has shown that vaccines prepared by transfer of DNA from the tumor into a highly immunogenic cell line stimulates an antitumor immune response which may be efficacious in the treatment of patients with brain tumors. Other research interests include developing a passive immunotherapeutic strategy for treatment of Alzheimer’s Disease. In addition, he has been involved in the development of a non-invasive MRI technique to measure intracranial pressure and brain compliance, and has been exploring the efficacy of this modality in managing a variety of patients with neurologic problems where intracranial pressure is an issue. Dr. Lichtor is a member of the neurosurgery faculty at Rush University Medical Center in Chicago, Illinois.
Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USAp53; Ferroptosis; Cancer
Dr. Yanqing Liu is affiliated with the Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA. His research interests focus on p53, Ferroptosis and Cancer.
Department of Clinical and Experimental Medicine, University of Foggia Medical School, Foggia, ItalyRole of angiogenesis in tumor dissemination; Mechanisms underlying the growth and progression of carcinomas and sarcomas of soft connective tissues
Faculty of Pharmacy, University of Reims Champagne-Ardenne, Reims, FranceCancer biology; Cell signaling; Proteins; Transfection; Molecular biology; Gene expression
Dr. Hamid Morjani is affiliated with the Faculty of Pharmacy, University of Reims Champagne-Ardenne, Reims, France. His research interests focus on Cancer biology, Cell signaling, Proteins, Transfection, Molecular biology and Gene expression.
Department of Experimental Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Via Armanni, 5, Naples, ItalyStem cells; Cancer stem cells; Cancer stem cells identification and eradication; Bone; Remodeling; Sarcomas; Adipose stem cells; Differentiation; Head and neck cancer
1. Biobank of Research, IRCCS Azienda Ospedaliera-Universitaria di Bologna Policlinico di S. Orsola, Bologna, Italy;
2. Department of Medical and Surgical Sciences, Alma Mater Studiorum Università di Bologna, Bologna, ItalyLeukemia; Lymphoma; Targeted therapy; Molecular diagnostics; High throughput genomics; Transcriptomics; Digital pathology
Associate Professor of Pathology & Executive Physician, Bologna University, S. Orsola Malpighi Hospital, Bologna, Italy
Adjunct Professor of Hematology and Pathology at Jomo Kenyatta University of Agricolture and Technology, Nairobi, Kenya
Member of the Scientific Committee, Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy
National Academic Qualification as Full Professor of Pathology
Associate Editor for the American Journal of Blood Research, Modern Chemotherapy, World Journal of Hematology, Frontiers in Molecular Biosciences, Helyon.
Member of the SIE, SIES, ASH, AACR, SIAPEC/IAP, EHA, ELN/EWALL, FIL
Pharmacology & Toxicology, Wright State University Boonshoft School of Medicine, Dayton, OH, USAPro-oxidative stressors and lipid mediators; Cancer pharmacology and chemoprevention; Anticancer therapeutics and immunomodulation; Photobiology and environmental factors; Cellular signaling pathways in tumor resistance mechanisms; Antitumor immune responses
Orthopaedic Oncology and Trauma Surgeon, IRCCS University Hospital Sant’Orsola, Bologna, ItalyAntibiotic-loaded cement; Bone tumors; Hip arthroplasty; Knee; Prostheses and implants; Sarcoma; Soft tissue sarcoma
Consultant, the Orthopaedic Department, University Hospital Sant'Orsola-Malpighi, Bologna
Department of Life Sciences, University of Trieste, Trieste, ItalyCancer biomarkers; Epigenetic; Epigenetic sequencing; Exosome; Extracellular vesicle; Liquid biopsy
Dr. Bruna Scaggiante is affiliated with Department of Life Sciences, University of Trieste, Trieste, Italy. Her research interests focus on Cancer biomarkers, Epigenetic, Epigenetic sequencing, Exosome, Extracellular vesicle and Liquid biopsy.
Department of Pharmacology, Yong Loo Lin School of Medicine, Queenstown, SingaporeCancer; Inflammation; Transcription factors; Vitamin; Apoptosis
Associate Professor at the Yong Loo Lin School of Medicine, Queenstown, Singapore.
Dr. Sethi is the editorial board member of 11 different international journals.
AVAILABILITY
-
Collaborative projects
-
Industry Projects
-
Masters Research or PhD student supervision
-
Join a web conference as a panellist or speaker
-
Mentoring (long-term)
-
Media enquiries
-
Mentoring (short-term)
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAIdentification of the cryptic novel proteins that play an important function in human cancer; Computational-based CRISPR screen / NLS library design; AI-based big data platform
Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, ChinaEsophageal cancer; Brain tumor; Bioinformatics; Protein-protein interaction network; Molecular biology
Dr. Bingli Wu is affiliated with Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, China . His research interests focus on Esophageal cancer, Brain tumor, Bioinformatics, Protein-protein interaction network and Molecular biology.
Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USATumor immunology and immunotherapy; CAR-T cell therapy; Cancer immunometabolism; Cancer metastasis and therapeutics; Genitourinary malignancies (like prostate cancer); Lung cancer; Pancreatic cancer
